IL6 and COVID-19: Due to the non-involvement of JAK2 in type I or type II interferon-related cell signaling, selective JAK2 inhibitors are the preferred treatment choice for suppressing IL-6-GM-CSF-signaling-in COVID-19-associated cytokine storms.